Medicina
Departamento
Queensland University of Technology
Brisbane, AustraliaPublicaciones en colaboración con investigadores/as de Queensland University of Technology (24)
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis
Annals of Oncology, Vol. 34, Núm. 2, pp. 173-185
-
Machine learning for diagnosis of myocardial infarction using cardiac troponin concentrations
Nature Medicine, Vol. 29, Núm. 5, pp. 1201-1210
-
Neurological manifestations of COVID-19 in adults and children
Brain, Vol. 146, Núm. 4, pp. 1648-1661
-
Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial
ESMO Open, Vol. 8, Núm. 6
-
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817
Journal of Thoracic Oncology, Vol. 18, Núm. 1, pp. 79-92
-
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1
Journal of Thoracic Oncology, Vol. 18, Núm. 8, pp. 1055-1069
2022
-
Acute Heart Failure in the 2021 ESC Heart Failure Guidelines: A scientific statement from the Association for Acute CardioVascular Care (ACVC) of the European Society of Cardiology
European Heart Journal: Acute Cardiovascular Care, Vol. 11, Núm. 2, pp. 173-185
-
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
Journal of Thoracic Oncology, Vol. 17, Núm. 2, pp. 289-308
2021
-
An appraisal of respiratory system compliance in mechanically ventilated covid-19 patients
Critical Care, Vol. 25, Núm. 1
2019
-
GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways
Nature Communications, Vol. 10, Núm. 1
-
Publisher Correction: Shared heritability and functional enrichment across six solid cancers (Nature Communications, (2019), 10, 1, (431), 10.1038/s41467-018-08054-4)
Nature Communications
-
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer
Lung Cancer, Vol. 132, pp. 126-131
-
Shared heritability and functional enrichment across six solid cancers
Nature Communications, Vol. 10, Núm. 1
2018
-
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials
Clinical Lung Cancer, Vol. 19, Núm. 4, pp. e465-e479
-
Erratum: Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung (Journal of Clinical Oncology (2017) DOI: 10.1200/JCO.2016.69.2160)
Journal of Clinical Oncology
-
Indications and practical approach to non-invasive ventilation in acute heart failure
European Heart Journal, Vol. 39, Núm. 1, pp. 17-25
2017
-
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial
Annals of Oncology, Vol. 28, Núm. 2, pp. 270-277
-
Results from the Phase III Randomized Trial of Onartuzumab plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung
Journal of Clinical Oncology, Vol. 35, Núm. 4
2016
-
140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations
Journal of Thoracic Oncology, Vol. 11, Núm. 4, pp. S117-S118